Citations (51)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (13)
Gang Li, Alexander Keenan, Mehmet Daskiran, Maju Mathews, Isaac Nuamah, Camille Orman, Kruti Joshi, Arun Singh, Annabelle Godet, Katalin Pungor & Srihari Gopal. (2021) Relapse and Treatment Adherence in Patients with Schizophrenia Switching from Paliperidone Palmitate Once-Monthly to Three-Monthly Formulation: A Retrospective Health Claims Database Analysis. Patient Preference and Adherence 15, pages 2239-2248.
Read now
Read now
Antoine C El Khoury, Charmi Patel, Panagiotis Mavros, Ahong Huang, Li Wang & Richa Bashyal. (2021) Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate Among Veterans with Schizophrenia. Neuropsychiatric Disease and Treatment 17, pages 3159-3170.
Read now
Read now
Charmi Patel, Bruno Emond, Laura Morrison, Marie-Hélène Lafeuille, Patrick Lefebvre, Dee Lin, Edward Kim & Kruti Joshi. (2021) Risk of subsequent relapses and corresponding healthcare costs among recently-relapsed Medicaid patients with schizophrenia: a real-world retrospective cohort study. Current Medical Research and Opinion 37:4, pages 665-674.
Read now
Read now
Antoine El Khoury, Charmi Patel, Ahong Huang, Li Wang & Richa Bashyal. (2019) Transitioning from oral risperidone or paliperidone to once-monthly paliperidone palmitate: a real-world analysis among Veterans Health Administration patients with schizophrenia who have had at least one prior hospitalization. Current Medical Research and Opinion 35:12, pages 2159-2168.
Read now
Read now
Antoine C. El Khoury, Dominic Pilon, Laura Morrison, Nina Shak, Maude Vermette-Laforme, Tony B. Amos, Edward Kim & Patrick Lefebvre. (2019) The prospective economic impact of once monthly paliperidone palmitate versus oral atypical antipsychotics in Medicaid patients with schizophrenia. Current Medical Research and Opinion 35:3, pages 395-405.
Read now
Read now
Dominic Pilon, Tony B. Amos, Rhiannon Kamstra, Ameur M. Manceur, Antoine C. El Khoury & Patrick Lefebvre. (2019) Short-term rehospitalizations in young adults with schizophrenia treated with once-monthly paliperidone palmitate or oral atypical antipsychotics: a retrospective analysis. Current Medical Research and Opinion 35:1, pages 41-49.
Read now
Read now
Robin Emsley & Sanja Kilian. (2018) Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review. Neuropsychiatric Disease and Treatment 14, pages 205-223.
Read now
Read now
Mallik Greene, Tingjian Yan, Eunice Chang, Ann Hartry, Maëlys Touya & Michael S. Broder. (2018) Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder. Journal of Medical Economics 21:2, pages 127-134.
Read now
Read now
Thomas R. Einarson, Basil G. Bereza, Fadi Tedouri, Kristel Van Impe, Tom R. Denee & Pieter J. T. Dries. (2017) Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands. Journal of Medical Economics 20:11, pages 1187-1199.
Read now
Read now
Kruti Joshi, Marie-Hélène Lafeuille, Brianne Brown, Willy Wynant, Bruno Emond, Patrick Lefebvre & Neeta Tandon. (2017) Baseline characteristics and treatment patterns of patients with schizophrenia initiated on once-every-three-months paliperidone palmitate in a real-world setting. Current Medical Research and Opinion 33:10, pages 1763-1772.
Read now
Read now
Jacqueline A. Pesa, Dilesh Doshi, Li Wang, Huseyin Yuce & Onur Baser. (2017) Health care resource utilization and costs of California Medicaid patients with schizophrenia treated with paliperidone palmitate once monthly or atypical oral antipsychotic treatment. Current Medical Research and Opinion 33:4, pages 723-731.
Read now
Read now
Kruti Joshi, Xiaoyun Pan, Rosa Wang, Erru Yang & Carmela Benson. (2016) Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate. Current Medical Research and Opinion 32:11, pages 1873-1881.
Read now
Read now
Yongling Xiao, Erik Muser, Dong-Jing Fu, Marie-Hélène Lafeuille, Dominic Pilon, Bruno Emond, Allen Wu, Mei Sheng Duh & Patrick Lefebvre. (2016) Comparison of Medicaid spending in schizoaffective patients treated with once monthly paliperidone palmitate or oral atypical antipsychotics. Current Medical Research and Opinion 32:4, pages 759-769.
Read now
Read now
Articles from other publishers (38)
Yifei Liu, Mark E. Patterson, Suman Sahil & Steven C. Stoner. (2023) Inpatient prescribing patterns of long-acting injectables and their oral or short-acting injectable equivalent formulations. Frontiers in Pharmacology 14.
Crossref
Crossref
Christoph U. Correll, Carmela Benson, Bruno Emond, Charmi Patel, Marie-Hélène Lafeuille, Dee Lin, Laura Morrison, Isabelle Ghelerter, Patrick Lefebvre & Panagiotis Mavros. (2023) Comparison of clinical outcomes in patients with schizophrenia following different long-acting injectable event-driven initiation strategies. Schizophrenia 9:1.
Crossref
Crossref
Siuly Siuly, Yan Li, Peng Wen & Omer Faruk Alcin. (2022) SchizoGoogLeNet: The GoogLeNet-Based Deep Feature Extraction Design for Automatic Detection of Schizophrenia. Computational Intelligence and Neuroscience 2022, pages 1-13.
Crossref
Crossref
Amber Martin, Leona Bessonova, Rachel Hughes, Michael J. Doane, Amy K. O’Sullivan, Kassandra Snook, Allie Cichewicz, Peter J. Weiden & Philip D. Harvey. (2022) Systematic Review of Real-World Treatment Patterns of Oral Antipsychotics and Associated Economic Burden in Patients with Schizophrenia in the United States. Advances in Therapy 39:9, pages 3933-3956.
Crossref
Crossref
Ana A. Miron, Petru I. Ifteni, Andreea Teodorescu & Paula S. Petric. (2022) Long-Acting Injectable Antipsychotics (LAIs) Prescribing Trends during the COVID-19 Pandemic in Romania. Healthcare 10:7, pages 1265.
Crossref
Crossref
Chizimuzo T.C. Okoli, Amani Kappi, Tianyi Wang, Andrew Makowski & Andrew T. Cooley. (2021) The effect of long‐acting injectable antipsychotic medications compared with oral antipsychotic medications among people with schizophrenia: A systematic review and meta‐analysis. International Journal of Mental Health Nursing 31:3, pages 469-535.
Crossref
Crossref
Charmi Patel, Ahong Huang, Li Wang, Yoshita Paliwal & Kruti Joshi. (2022) Patient Journey of Veterans with Schizophrenia: An Analysis of Treatment Patterns, Healthcare Resource Utilization and Costs. Advances in Therapy 39:3, pages 1199-1214.
Crossref
Crossref
Fethia Mohammed, Biftu Geda, Tesfaye Assebe Yadeta & Yadeta Dessie. (2022) Exploring the trend of Schizophrenia at Hiwot Fana specialized university referral hospital, Eastern, Ethiopia (2016–2020): A 5-year retrospective analysis. SAGE Open Medicine 10, pages 205031212211321.
Crossref
Crossref
Kyle A. McKee, Candice E. Crocker & Philip G. Tibbo. (2021) Long-acting injectable antipsychotic (LAI) prescribing trends during COVID-19 restrictions in Canada: a retrospective observational study. BMC Psychiatry 21:1.
Crossref
Crossref
Murat Sırrı Akosman, Ruhi Türkmen & Hasan Hüseyin Demirel. (2021) Investigation of the protective effect of resveratrol in an MK-801-induced mouse model of schizophrenia. Environmental Science and Pollution Research 28:46, pages 65872-65884.
Crossref
Crossref
John Lauriello, Peter J. Weiden, Carole D. Gleeson, Ankit Shah, Luke Boulanger, Krutika Jariwala-Parikh, Elizabeth Hedgeman & Amy K. O’Sullivan. (2021) Real-World Outcomes and Costs Following 6 Months of Treatment with the Long-Acting Injectable (LAI) Aripiprazole Lauroxil for the Treatment of Schizophrenia. CNS Drugs 35:10, pages 1123-1135.
Crossref
Crossref
Taishiro Kishimoto, Katsuhiko Hagi, Shunya Kurokawa, John M Kane & Christoph U Correll. (2021) Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre–post studies. The Lancet Psychiatry 8:5, pages 387-404.
Crossref
Crossref
Dee Lin, Philippe Thompson-Leduc, Isabelle Ghelerter, Ha Nguyen, Marie-Hélène Lafeuille, Carmela Benson, Panagiotis Mavros & Patrick Lefebvre. (2021) Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis. CNS Drugs 35:5, pages 469-481.
Crossref
Crossref
Abhijeet Bhanegaonkar, Shivani Pandya, Ying Zheng, Ruth Kim, Stan Krulewicz, Vijay Kasturi & Hemant Phatak. (2021) Real-World Outcomes Among US Veterans Health Administration Patients Newly Diagnosed with Metastatic Renal Cell Carcinoma and Treated with First-Line Monotherapy. Advances in Therapy 38:5, pages 2644-2661.
Crossref
Crossref
Rohan Mahabaleshwarkar, Dee Lin, Jesse Fishman, Todd Blair, Timothy Hetherington, Pooja Palmer, Charmi Patel, Carmela Benson, Kruti Joshi, Constance Krull & Oleg V. Tcheremissine. (2021) The Impact of Once-Monthly Paliperidone Palmitate on Healthcare Utilization Among Patients With Schizophrenia Treated in an Integrated Healthcare System: A Retrospective Mirror-Image Study. Advances in Therapy 38:4, pages 1958-1974.
Crossref
Crossref
A. Orrico-Sánchez, M. López-Lacort, C. Muñoz-Quiles, G. Sanfélix-Gimeno & J. Díez-Domingo. (2020) Epidemiology of schizophrenia and its management over 8-years period using real-world data in Spain. BMC Psychiatry 20:1.
Crossref
Crossref
Sunandana Chandra, Ying Zheng, Shivani Pandya, Ting Yu, Mairead Kearney, Li Wang, Ruth Kim & Hemant Phatak. (2020) Real-world outcomes among US Merkel cell carcinoma patients initiating immune checkpoint inhibitors or chemotherapy. Future Oncology 16:31, pages 2521-2536.
Crossref
Crossref
Dasom Lee, Boung Chul Lee, Soo-Hee Choi, Do-Hyung Kang, Duk-In Jon & Myung Hun Jung. (2020) Effects of Paliperidone Palmitate on Healthcare Utilization and Costs for Patients with Schizophrenia: A Claim-based Mirror-image Study in South Korea. Clinical Psychopharmacology and Neuroscience 18:2, pages 303-310.
Crossref
Crossref
Antoine C. El KhouryDominic PilonLaura MorrisonNina Shak, Amanda LlanezaEdward KimPatrick Lefebvre. (2020) Projecting the Long-Term Economic Impact of Once-Monthly Paliperidone Palmitate Versus Oral Atypical Antipsychotics in Medicaid Patients with Schizophrenia. Journal of Managed Care & Specialty Pharmacy 26:2, pages 176-185.
Crossref
Crossref
Charmi Patel, Antoine El Khoury, Ahong Huang, Li Wang, Onur Baser & Kruti Joshi. (2019) Health Outcomes Among Patients Diagnosed with Schizophrenia in the US Veterans Health Administration Population Who Transitioned from Once-Monthly to Once-Every-3-Month Paliperidone Palmitate: An Observational Retrospective Analysis. Advances in Therapy 36:10, pages 2941-2953.
Crossref
Crossref
Bruno Emond, Kruti Joshi, Antoine C. El Khoury, Marie-Hélène Lafeuille, Dominic Pilon, Neeta Tandon, Hela Romdhani & Patrick Lefebvre. (2018) Adherence, Healthcare Resource Utilization, and Costs in Medicaid Beneficiaries with Schizophrenia Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate. PharmacoEconomics - Open 3:2, pages 177-188.
Crossref
Crossref
Celso Arango, Inmaculada Baeza, Miquel Bernardo, Fernando Cañas, Consuelo de Dios, Marina Díaz-Marsá, María Paz García-Portilla, Luis Gutiérrez-Rojas, José Manuel Olivares, Fernando Rico-Villademoros, Roberto Rodríguez-Jiménez, Eva María Sánchez-Morla, Rafael Segarra & Benedicto Crespo-Facorro. (2019) Long-acting injectable antipsychotics for the treatment of schizophrenia in Spain. Revista de Psiquiatría y Salud Mental (English Edition) 12:2, pages 92-105.
Crossref
Crossref
Celso Arango, Inmaculada Baeza, Miquel Bernardo, Fernando Cañas, Consuelo de Dios, Marina Díaz-Marsá, María Paz García-Portilla, Luis Gutiérrez-Rojas, José Manuel Olivares, Fernando Rico-Villademoros, Roberto Rodríguez-Jiménez, Eva María Sánchez-Morla, Rafael Segarra & Benedicto Crespo-Facorro. (2019) Antipsicóticos inyectables de liberación prolongada para el tratamiento de la esquizofrenia en España. Revista de Psiquiatría y Salud Mental 12:2, pages 92-105.
Crossref
Crossref
Qian Cai, Charmi Patel, Edward Kim, Nancy Connolly, Ozgur Tunceli & Antoine C. El Khoury. (2019) Factors Associated with the Initiation of Long-Acting Injectable Paliperidone Palmitate Versus Aripiprazole Among Medicaid Patients with Schizophrenia: An Observational Study. Advances in Therapy 36:4, pages 858-869.
Crossref
Crossref
Ankit Shah, Lin Xie, Furaha Kariburyo, Qisu Zhang & Mugdha Gore. (2018) Treatment Patterns, Healthcare Resource Utilization and Costs Among Schizophrenia Patients Treated with Long-Acting Injectable Versus Oral Antipsychotics. Advances in Therapy 35:11, pages 1994-2014.
Crossref
Crossref
Kruti Joshi, Erik Muser, Yihua Xu, Phil Schwab, Manasi Datar & Brandon Suehs. (2018) Adherence and economic impact of paliperidone palmitate versus oral atypical antipsychotics in a Medicare population. Journal of Comparative Effectiveness Research 7:8, pages 723-735.
Crossref
Crossref
Taishiro Kishimoto, Katsuhiko Hagi, Masahiro Nitta, Stefan Leucht, Mark Olfson, John M Kane & Christoph U Correll. (2018) Effectiveness of Long-Acting Injectable vs Oral Antipsychotics in Patients With Schizophrenia: A Meta-analysis of Prospective and Retrospective Cohort Studies. Schizophrenia Bulletin 44:3, pages 603-619.
Crossref
Crossref
Marie-Hélène Lafeuille, Neeta Tandon, Sean Tiggelaar, Rhiannon Kamstra, Patrick Lefebvre, Edward Kim, Yong Yue & Kruti Joshi. (2018) Economic Impact in Medicaid Beneficiaries with Schizophrenia and Cardiometabolic Comorbidities Treated with Once-Monthly Paliperidone Palmitate vs. Oral Atypical Antipsychotics. Drugs - Real World Outcomes 5:1, pages 81-90.
Crossref
Crossref
Kruti Joshi, Marie-Hélène Lafeuille, Rhiannon Kamstra, Sean Tiggelaar, Patrick Lefebvre, Edward Kim, Yong Yue & Neeta Tandon. (2018) Real-world adherence and economic outcomes associated with paliperidone palmitate versus oral atypical antipsychotics in schizophrenia patients with substance-related disorders using Medicaid benefits. Journal of Comparative Effectiveness Research 7:2, pages 121-133.
Crossref
Crossref
Robin Emsley, Eduard Parellada, Miquel Bioque, Berta Herrera, Teresa Hernando & Marta García-Dorado. (2018) Real-world data on paliperidone palmitate for the treatment of schizophrenia and other psychotic disorders. International Clinical Psychopharmacology 33:1, pages 15-33.
Crossref
Crossref
Dominic Pilon, Erik Muser, Patrick Lefebvre, Rhiannon Kamstra, Bruno Emond & Kruti Joshi. (2017) Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia. BMC Psychiatry 17:1.
Crossref
Crossref
Dominic Pilon, Neeta Tandon, Marie-Hélène Lafeuille, Rhiannon Kamstra, Bruno Emond, Patrick Lefebvre & Kruti Joshi. (2017) Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics. Clinical Therapeutics 39:10, pages 1972-1985.e2.
Crossref
Crossref
Mark Pennington & Paul McCrone. (2017) The Cost of Relapse in Schizophrenia. PharmacoEconomics 35:9, pages 921-936.
Crossref
Crossref
Patrick Lefebvre, Erik Muser, Kruti Joshi, Maral DerSarkissian, Rachel H. Bhak, Mei Sheng Duh, Brian Shiner & Yinong Young-Xu. (2017) Impact of Paliperidone Palmitate Versus Oral Atypical Antipsychotics on Health Care Resource Use and Costs in Veterans With Schizophrenia and Comorbid Substance Abuse. Clinical Therapeutics 39:7, pages 1380-1395.e4.
Crossref
Crossref
Jesús E. Mesones-Peral, Pedro Gurillo-Muñoz, Mari Paz Sánchez-Sicilia, Adam Miller & Alejandra Griñant-Fernández. (2017) Hospitalizations and economic analysis in psychotic patients with paliperidone palmitate long-acting injection. Revista de Psiquiatría y Salud Mental (English Edition) 10:1, pages 33-37.
Crossref
Crossref
Jesús E. Mesones-Peral, Pedro Gurillo-Muñoz, Mari Paz Sánchez-Sicilia, Adam Miller & Alejandra Griñant-Fernández. (2017) Hospitalizaciones y análisis económico en pacientes psicóticos con palmitato de paliperidona de larga duración. Revista de Psiquiatría y Salud Mental 10:1, pages 33-37.
Crossref
Crossref
Eduard Parellada & Miquel Bioque. (2016) Barriers to the Use of Long-Acting Injectable Antipsychotics in the Management of Schizophrenia. CNS Drugs 30:8, pages 689-701.
Crossref
Crossref
Jacqueline A. Pesa, Erik Muser, Leslie B. Montejano, David M. Smith & Oren I. Meyers. (2015) Costs and Resource Utilization Among Medicaid Patients with Schizophrenia Treated with Paliperidone Palmitate or Oral Atypical Antipsychotics. Drugs - Real World Outcomes 2:4, pages 377-385.
Crossref
Crossref